Gerardo Hernandez has served as TransMedics' Chief Financial Officer and Treasurer since December 2024, succeeding Stephen Gordon.
Prior to joining TransMedics he served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals from February 2020 to September 2024, supporting the company's transformation from a U.S. clinical-stage organization to a global commercial enterprise, and earlier was Head of Corporate Financial Planning & Analysis Integration at Takeda Pharmaceuticals from January 2019 to January 2020.
Before that he held various roles at Shire plc, including Head of Corporate Financial Planning & Analysis from December 2010 until its acquisition by Takeda in January 2019, and held finance roles at Unilever plc from September 1994 until June 2010; he holds a B.S. in Finance from the University of Wisconsin, La Crosse and an MBA from Fundação Getulio Vargas, Sao Paulo, Brazil.
Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.